Calcineurin Inhibitor Triple Therapy Ranks Highest for Lupus Nephritis Remission
Analysis Rheumatology / Immunology Confirmatory Grade: Moderate
Aug 5, 2026 · Published in: Lupus
Triple therapy with Tacrolimus or Voclosporin excels in lupus nephritis remission.
Extension Data Bolster Case Against Amyloid Therapy Coverage Restrictions
Analysis Neurology / Neuropharmacology Confirmatory Grade: Low
Boustani M, Klein EG, Zimmer JA, et al.
Aug 5, 2026 · Published in: Alzheimer's & Dementia
Amyloid therapies show promise in Alzheimer's treatment.
Seizure Prophylaxis in Aneurysmal SAH: New Guidelines
Analysis Oncology
Rowe AS, Zafar SF, Tesoro E, et al.
Aug 5, 2026 · Published in: Neurocritical Care
Seizure prophylaxis in aneurysmal SAH: ASM or not?
Glucocorticoid Use Impacts NSCLC Survival on ICIs
Analysis Oncology
Lee DE, Lim G, Ko M, et al.
Aug 5, 2026 · Published in: Clinical Pharmacology and Therapeutics
High-dose glucocorticoids may harm NSCLC patients on ICIs.
Early In-Hospital ARNI After MI: Promising but PARADISE-MI Anchors Caution
Analysis Cardiology / Anticoagulation Hypothesis-generating Grade: Low
Nguyen Q, Tran TTQ, Liao CT, et al.
Aug 5, 2026 · Published in: Frontiers in Cardiovascular Medicine
Early ARNI therapy post-AMI cuts cardiovascular events by 42%.
Antimicrobial Use Trends in U.S. Hospitals, 2023
Analysis Infectious Disease / Antimicrobials
Keino BC, Eure T, Ramirez RA, et al.
Aug 5, 2026 · Published in: Open Forum Infectious Diseases
Antimicrobial use in hospitals remains high in 2023.
Three-strain probiotic modestly eases menopausal symptoms in real-world trial
Analysis Women's Health / Reproductive Hypothesis-generating Grade: Low
Rodríguez-Palmero M, Prat C, Molina X, et al.
Aug 4, 2026 · Published in: Menopause (New York, N.Y.)
Probiotics may ease menopause symptoms and improve quality of life.
Cladribine tablets sustain remission through two treatment-free years
Analysis Neurology / Neuropharmacology Confirmatory Grade: Low
De Stefano N, Vermersch P, Wiendl H, et al.
Aug 4, 2026 · Published in: Multiple Sclerosis (Houndmills, Basingstoke, England)
Cladribine tablets show promise for sustained treatment-free remission in RMS.
Pharmacist Inhaler Review Cuts Readmissions in COPD, Not Overall
Analysis Pulmonology / Respiratory Hypothesis-generating Grade: Moderate
Parrott TD, Wallace MD, Eble SH, et al.
Aug 4, 2026 · Published in: CHEST Pulmonary
Pharmacist intervention cuts COPD readmissions effectively.
New Anaerobic Activity Index Quantifies Anti-Anaerobic Antibiotic Exposure
Analysis Infectious Disease / Antimicrobials Hypothesis-generating Grade: Low
Mackow NA, Komarow L, Napravnik S, et al.
Aug 4, 2026 · Published in: Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America
A new index ranks antibiotics by anaerobic activity exposure.
Dapagliflozin plus pioglitazone improves glycemia and hepatic steatosis markers
Analysis Clinical Practice Confirmatory Grade: Moderate
Joshi S, Samajdar SS, Gupta A, et al.
Aug 4, 2026 · Published in: Frontiers in Clinical Diabetes and Healthcare
Improved glycemic and liver outcomes found with combination therapy in T2DM.
TRAVERSE: Testosterone Is CV-Safe, But Safety Signals and Overdiagnosis Remain
Reference Card Endocrinology / Diabetes / Obesity
Aug 2, 2026 · Published in: PharmD Signal Reference Card
What the TRAVERSE trial actually shows, what it does not, and why pharmacists need to address the 'Low T' marketing phenomenon.
DOAC Dosing in CKD/ESRD: Apixaban Leads, But the Evidence Is Thin
Reference Card Cardiology / Anticoagulation
Aug 2, 2026 · Published in: PharmD Signal Reference Card
A pharmacist's guide to DOAC selection, dosing, and the inappropriate dose reduction problem in renal impairment.
GLP-1 RAs: Evidence-Based Prescribing vs. The Compounded Peptide Crisis
Reference Card Endocrinology / Diabetes / Obesity
Aug 2, 2026 · Published in: PharmD Signal Reference Card
Navigating legitimate GLP-1 RA controversies alongside the safety crisis in compounded and unregulated peptide products.
From Glucose-Centric to Outcomes-Driven: ADA 2026 Reshapes Diabetes Therapy
Reference Card Endocrinology / Diabetes / Obesity
Aug 2, 2026 · Published in: PharmD Signal Reference Card
How GLP-1 RAs and SGLT2 inhibitors displaced metformin as the default first-line in type 2 diabetes management.